3
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
1
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Esophageal Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Adenocarcinoma Of Esophagus
1
Adenocarcinoma
1
Interventions
Oxaliplatin
2
Fluorouracil
2
rubitecan
1
nimotuzumab
1
halofantrine
1
gallium 68 PSMA-11
1
camrelizumab
1
apatinib
1
S 1 (combination)
1
Radiotherapy
1
Radiosurgery
1
Radiation
1
Photochemotherapy
1
Nadroparin
1
Heparin, Low-Molecular-Weight
1
Gastrectomy
1
Esophagectomy
1
Docetaxel
1
Cisplatin
1
Chemoradiotherapy
1
Capecitabine
1
CP protocol
1
Brachytherapy
1
Atrasentan
1
Androgen Antagonists
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2/3
×
Adenocarcinoma
×
CP protocol
×
Clear all
NCT01404156
2024-08-28
POWERRANGER
CancerCare Manitoba
Phase 2/3
Completed
29 enrolled